🔗 Share this article

This year's prestigious award in medical science was granted for transformative findings that illuminate how the immune system targets dangerous infections while sparing the body's own cells.

Three renowned scientists—Japan's Prof. Sakaguchi and American scientists Dr. Brunkow and Fred Ramsdell—received this accolade.

Their work uncovered unique "security guards" within the immune system that eliminate malfunctioning defense cells capable of harming the organism.

The findings are now enabling new therapies for immune disorders and cancer.

These laureates will share a monetary award valued at 11 million SEK.

Crucial Discoveries

"Their work has been decisive for understanding how the immune system functions and why we don't all develop severe autoimmune diseases," commented the head of the Nobel Committee.

This team's studies explain a fundamental mystery: In what way does the defense system defend us from numerous invaders while keeping our healthy cells unharmed?

The immune system employs white blood cells that scan for signs of disease, even viruses and germs it has not met before.

These cells utilize sensors—called recognition units—that are produced by chance in a vast number of combinations.

This provides the defense network the ability to combat a wide array of invaders, but the unpredictability of the process unavoidably creates immune cells that can attack the body.

Security Guards of the Body

Scientists earlier understood that some of these problematic white blood cells were destroyed in the immune organ—where immune cells mature.

This year's Nobel Prize honors the identification of T-reg cells—known as the immune system's "security guards"—which patrol the system to neutralize other defenders that assault the body's own tissues.

We know that this process fails in self-attack conditions such as type-1 diabetes, MS, and rheumatoid arthritis.

A Nobel panel stated, "These findings have laid the foundation for a novel area of research and spurred the creation of new treatments, for example for cancer and autoimmune diseases."

In malignancies, T-regs prevent the system from attacking the tumor, so research are aimed at lowering their numbers.

For autoimmune diseases, trials are exploring boosting regulatory T-cells so the body is no longer being harmed. A comparable approach could also be useful in reducing the risks of transplanted organ failure.

Innovative Experiments

Professor Shimon Sakaguchi, of a Japanese institution, conducted tests on rodents that had their immune gland removed, leading to self-attack conditions.

He demonstrated that injecting defense cells from other animals could stop the disease—suggesting there was a system for preventing defenders from attacking the host.

Dr. Brunkow, from the Institute for Systems Biology in a US city, and Fred Ramsdell, now at a biotech firm in a California city, were investigating an inherited immune disorder in mice and humans that resulted in the identification of a gene critical for how regulatory T-cells operate.

"Their pioneering work has uncovered how the immune system is kept in check by regulatory T cells, stopping it from mistakenly attacking the body's own tissues," commented a prominent physiology specialist.

"The research is a remarkable illustration of how basic biological study can have far-reaching consequences for public health."